# Effects of Angiotensin Converting Enzyme (ACE) Inhibitors Versus Candesartan in Reducing Cardiovascular Events in Primary Treatment of Hypertension

> **NCT01152567** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 50000 (actual)

## Conditions studied

- Hypertension
- Cardiovascular Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01152567
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 50000 (ACTUAL)
- **Last updated:** 2011-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01152567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01152567, "Effects of Angiotensin Converting Enzyme (ACE) Inhibitors Versus Candesartan in Reducing Cardiovascular Events in Primary Treatment of Hypertension". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT01152567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*